$3.43 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 93 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KMPH | Exit | KEMPHARM INC | $0 | – | -418,613 | -100.0% | -0.00% | – |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -380,300 | -100.0% | -0.02% | – |
| MLND | Exit | MILLENDO THERAPEUTICS INC | $0 | – | -168,871 | -100.0% | -0.03% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -167,637 | -100.0% | -0.06% | – |
| CHNG | Exit | CHANGE HEALTHCARE INC | $0 | – | -214,789 | -100.0% | -0.07% | – |
| Exit | INTERCEPT PHARMACEUTICALS INnote 2.000% 5/1 | $0 | – | -3,500,000 | -100.0% | -0.09% | – | |
| SYRS | Exit | SYROS PHARMACEUTICALS INC | $0 | – | -1,268,946 | -100.0% | -0.24% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -963,212 | -100.0% | -0.26% | – |
| AXGN | Exit | AXOGEN INC | $0 | – | -937,983 | -100.0% | -0.31% | – |
| TARA | Exit | ARTARA THERAPEUTICS INC | $0 | – | -432,670 | -100.0% | -0.32% | – |
| PASG | Exit | PASSAGE BIO INC | $0 | – | -670,367 | -100.0% | -0.34% | – |
| UHS | Exit | UNIVERSAL HLTH SVCS INCcl b | $0 | – | -138,874 | -100.0% | -0.44% | – |
| FTSV | Exit | FORTY SEVEN INC | $0 | – | -155,380 | -100.0% | -0.47% | – |
| FREQ | Exit | FREQUENCY THERAPEUTICS INC | $0 | – | -945,718 | -100.0% | -0.54% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -1,124,879 | -100.0% | -0.56% | – |
| Exit | JAZZ INVESTMENTS I LTDnote 1.875% 8/1 | $0 | – | -20,000,000 | -100.0% | -0.61% | – | |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -151,779 | -100.0% | -0.64% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -235,000 | -100.0% | -0.73% | – |
| DXCM | Exit | DEXCOM INC | $0 | – | -87,000 | -100.0% | -0.74% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -412,867 | -100.0% | -0.84% | – |
| Exit | INSMED INCnote 1.750% 1/1 | $0 | – | -61,000,000 | -100.0% | -1.62% | – | |
| ABMD | Exit | ABIOMED INC | $0 | – | -376,000 | -100.0% | -1.73% | – |
| Exit | DEXCOM INCnote 0.750%12/0 | $0 | – | -34,000,000 | -100.0% | -1.87% | – | |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -4,037,305 | -100.0% | -1.99% | – |
| Exit | NUVASIVE INCnote 2.250% 3/1 | $0 | – | -85,000,000 | -100.0% | -2.82% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.